Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered a choice of receiving either ChAdOx1 nCoV-19 or mRNA-1273 9 to 12 weeks after the initial dose. Levels of S-specific and RBD-specific IgG increased by a factor of 5 after a ChAdOx1 nCoV-19 boost and by a factor of 115 to 125...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 385; no. 11; pp. 1049 - 1051
Main Authors: Normark, Johan, Vikström, Linnea, Gwon, Yong-Dae, Persson, Ida-Lisa, Edin, Alicia, Björsell, Tove, Dernstedt, Andy, Christ, Wanda, Tevell, Staffan, Evander, Magnus, Klingström, Jonas, Ahlm, Clas, Forsell, Mattias
Format: Journal Article
Language:English
Published: Boston Massachusetts Medical Society 09.09.2021
Subjects:
Antibodies
Coronavirus
Coronaviruses
Correspondence
COVID-19 vaccines
Drug dosages
Health care
Immunization
Immunoglobulin G
Infectious Disease
Infectious Diseases
Infektionssjukdomar
Laboratories
Medical personnel
mRNA
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Sweden
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered a choice of receiving either ChAdOx1 nCoV-19 or mRNA-1273 9 to 12 weeks after the initial dose. Levels of S-specific and RBD-specific IgG increased by a factor of 5 after a ChAdOx1 nCoV-19 boost and by a factor of 115 to 125 after an mRNA-1273 boost.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2110716